Clinical Trial Update: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating LVGN6051 in combination therapy for head and neck squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• LVGN6051

Snippet

Sponsor: Lyvgen Biopharma Holdings Limited | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING